Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trainee Identification of the Self-efficacy Domains Needed to Succeed in Undergraduate and Graduate Medical Education.

Medical science educator·2025
Same author

Acute Kidney Injury after Cardiac Surgery.

Cardiorenal medicine·2024
Same author

Significance of Chronic Kidney Disease on Morbidity and Mortality in Hospitalized Patients With COVID-19.

HCA healthcare journal of medicine·2024
Same author

Association of Thiazide Diuretics With Diabetes Progression, Kidney Disease Progression, Cardiovascular Outcomes, and Death Among Patients With Diabetes Who Initiate Statins.

The American journal of cardiology·2023
Same author

A Fatal Case of Lisinopril-Induced Acute Necrotizing Pancreatitis.

Cureus·2023
Same author

Commentary: Renin Angiotensin System Inhibitors and Cardiac Surgery-"More Than Meets the Eye".

Seminars in thoracic and cardiovascular surgery·2021
Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026
Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026
Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026
Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026
Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026
Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Rituximab in immunologic glomerular diseases.

A Ahsan Ejaz1, Abdo Asmar2, Mourad M Alsabbagh1

  • 1Department of Nephrology; Hypertension and Transplantation; University of Florida; Gainesville, FL USA.

Mabs
|March 2, 2012
PubMed
Summary
This summary is machine-generated.

B-cell antigen CD20 is implicated in glomerular diseases. Therapies targeting CD20, like rituximab, show promise in treating various nephropathies and improving outcomes in kidney transplant patients.

Keywords:
glomerular diseasesrejectionrituximabtransplant

Related Experiment Videos

Last Updated: May 24, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

  • Nephrology
  • Immunology
  • Pathogenesis of Glomerular Diseases

Background:

  • The B-cell antigen CD20 is increasingly recognized for its role in the development of various diseases.
  • Glomerular diseases represent a significant area where CD20's involvement is being investigated.

Purpose of the Study:

  • To explore the therapeutic potential of B-cell-depleting strategies targeting CD20 in nephrology.
  • To evaluate the efficacy of CD20-targeted therapies for specific glomerular diseases and kidney transplant complications.

Main Methods:

  • Review of experimental data and clinical findings related to CD20 and B-cell depletion.
  • Analysis of treatment outcomes for conditions including lupus nephritis, membranous nephropathy, and post-transplant glomerulonephritis.

Main Results:

  • CD20-targeted B-cell depletion is a key strategy for treating multiple glomerular diseases.
  • Rituximab, a CD20-targeting therapy, has demonstrated clinical improvement in affected patients.

Conclusions:

  • B-cell-depleting therapies targeting CD20 offer a viable treatment option in nephrology.
  • Rituximab represents a potential adjunct or alternative therapy for various kidney diseases and transplant-related conditions.